EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513509-30-00

Acronym

1407-GUCG

Enrollment

201

Registered

2024-08-27

Start date

2016-01-11

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive or recurrent germ cell tumor (measurable or non-measurable)

Brief summary

Overall survival (OS)

Detailed description

Progression Free Survival (PFS), Favorable Response Rate (FRR), Treatment-related mortality, Toxicity

Interventions

DRUGETOPOSIDE

DRUGPACLITAXEL

DRUGIFOSFAMIDE

DRUGCISPLATIN

DRUGCARBOPLATIN

Eligibility

Sex/Gender

Male

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Progression Free Survival (PFS), Favorable Response Rate (FRR), Treatment-related mortality, Toxicity	—

Countries

Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026